Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Narlumosbart Combined With Neoadjuvant Chemotherapy in Bone Malignancies
NCT06302465Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- May 2024
- Primary completion
- Nov 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Randomised, open-label trial of narlumosbart in bone cancer (2 arms), sponsored by Peking University People's Hospital. Primary endpoint: local recurrence rate at 2 years. Started May 2024; status: recruiting.
02
Drugs
narlumosbart
03
Conditions
bone cancer
Beyond the preview
Go deeper on NCT06302465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06302465.